Sobi: Wills Hughes-Wilson appointed Vice President Government Affairs & Policy

Wills Hughes-Wilson has been appointed Vice President, Government Affairs &
Policy with responsibility for Sobi's contacts with all stakeholders in the
health policy area.

Wills comes from Genzyme Corporation, now part of the French Sanofi Group, where
she was Vice President Health/Market Access Policy, Europe. She joined Genzyme
in 2005. Prior to Genzyme she was Executive Director of Emerging
Biopharmaceutical Enterprises (EBE), a specialized group of the European
Federation of Pharmaceuticals Industries & Associations (EFPIA) representing the
interest of biotechnology companies in Europe. She has also worked in the animal
health/veterinary medicines industry and at Ernst & Young Consulting.

Will Hughes Wilson, born in 1971, is an Honors graduate in Law from University
of Durham in the UK. She will report to CEO Geoffrey McDonough and will be a
member of the Executive Leadership Team, based in Brussels. She will assume her
position in February 2012.

"We are very pleased to welcome Wills to Sobi. As one of the leading health
policy experts in Europe within the orphan disease area, Wills is Chair of the
joint EBE and EuropaBio Industry Task Force on Orphan Drugs and Rare Diseases,
and is one of four industry members of the European Commission's newly
established Committee of Experts on Rare Diseases (EUCERD). Wills will represent
the patient focus and commitment to rare diseases of Sobi in the policy arena,"
says Geoffrey McDonough, CEO of Sobi.



For further information, please contact:
Åsa Stenqvist, Head of Communications and Investor Relations
Tel.: +46 8 697 21 88



Swedish Orphan Biovitrum (Sobi)
Sobi is a leading integrated biopharmaceutical company dedicated to bringing
innovative therapies and services to improve the health of rare disease patients
and their families. The product portfolio comprises about 60 marketed products
as well as projects in the late clinical phase. Key therapeutic areas are
Inflammation and Genetics & Metabolism. In 2010 Sobi had revenues of SEK 1.9
billion and around 500 employees. The share (STO: SOBI) is listed on OMX NASDAQ
Stockholm. More information is available atwww.sobi.com.



The information above has been published pursuant to the Swedish Securities
Market Act and/or the Financial Instruments Trading Act. The information was
released for public distribution on 31 January 2012 at 10.00 CET.




[HUG#1581289]